Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1936372, 14 pages
https://doi.org/10.1155/2017/1936372
Review Article

Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy

1Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
2Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
3Department of Nephrology, UZ Leuven, Leuven, Belgium
4Department of Immunology and Microbiology, KU Leuven, Leuven, Belgium
5Department of Pediatrics, Yonsei University College of Medicine, Severance Children’s Hospital, Seoul, Republic of Korea

Correspondence should be addressed to Andreas Kronbichler; ta.ca.dem-i@relhcibnork.saerdna

Received 27 February 2017; Accepted 18 July 2017; Published 17 August 2017

Academic Editor: Christophe Duranton

Copyright © 2017 Andreas Kronbichler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ponticelli and R. J. Glassock, “Glomerular diseases: membranous nephropathy-a modern view,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 609–616, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Alfaadhel and D. Cattran, “Management of Membranous Nephropathy in Western Countries,” Kidney Diseases, vol. 1, no. 2, pp. 126–137, 2015. View at Publisher · View at Google Scholar
  3. C. C. Huang, A. Lehman, A. Albawardi et al., “IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression,” Modern Pathology, vol. 26, no. 6, pp. 799–805, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Davies and B. J. Sutton, “Human IgG4: A structural perspective,” Immunological Reviews, vol. 268, no. 1, pp. 139–159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Stone, Y. Zen, and V. Deshpande, “Mechanisms of disease: IgG4-related disease,” The New England Journal of Medicine, vol. 366, no. 6, pp. 539–551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Kamisawa, Y. Zen, S. Pillai, and J. H. Stone, “IgG4-related disease,” The Lancet, 2014. View at Publisher · View at Google Scholar
  7. A. McGrogan, C. F. M. Franssen, and C. S. De Vries, “The incidence of primary glomerulonephritis worldwide: A systematic review of the literature,” Nephrology Dialysis Transplantation, vol. 26, no. 2, pp. 414–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. C. Cattran, H. N. Reich, H. J. Beanlands, J. A. Miller, J. W. Scholey, and S. Troyanov, “The impact of sex in primary glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 23, no. 7, pp. 2247–2253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Moranne, L. Watier, J. Rossert, and B. Stengel, “Primary glomerulonephritis: An update on renal survival and determinants of progression,” QJM, vol. 101, no. 3, pp. 215–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-H. Chou, Y.-C. Lien, F.-C. Hu et al., “Clinical outcomes and predictors for ESRD and mortality in primary GN,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1401–1408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Sim, M. Batech, A. Hever et al., “Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population,” American Journal of Kidney Diseases, vol. 68, no. 4, pp. 533–544, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kronbichler, M. A. Saleem, B. Meijers, and J. I. Shin, “Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View,” Journal of Immunology Research, vol. 2016, Article ID 2068691, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Moroni, B. Gallelli, S. Quaglini et al., “Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN),” Nephrology Dialysis Transplantation, vol. 25, no. 10, pp. 3408–3415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Debiec, J. Nauta, F. Coulet et al., “Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies,” Lancet, vol. 364, no. 9441, pp. 1252–1259, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. L. H. Beck Jr., R. G. B. Bonegio, G. Lambeau et al., “M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 361, no. 1, pp. 11–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. M. Tomas, L. H. Beck Jr., C. Meyer-Schwesinger et al., “Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 371, no. 24, pp. 2277–2287, 2014. View at Publisher · View at Google Scholar
  17. J. M. Hofstra, H. Debiec, C. D. Short et al., “Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1735–1743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Hoxha, U. Kneiler, G. Stege et al., “Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy,” Kidney International, vol. 82, no. 7, pp. 797–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Hofstra, L. H. Beck Jr., D. M. Beck, J. F. Wetzels, and D. J. Salant, “Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1286–1291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Hoxha, I. Thiele, G. Zahner, U. Panzer, S. Harendza, and R. A. K. Stahl, “Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy,” Journal of the American Society of Nephrology, vol. 25, no. 6, pp. 1357–1366, 2014. View at Publisher · View at Google Scholar
  21. Y. J. Oh, S. H. Yang, D. K. Kim, S.-W. Kang, and Y. S. Kim, “Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy,” PLoS ONE, vol. 8, no. 4, Article ID e62151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Ramachandran, V. Kumar, A. Kumar et al., “PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians,” Nephrology Dialysis Transplantation, vol. 31, no. 9, pp. 1486–1493, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Li, D. Wei, Z. Zhou et al., “Anti-PLA2R antibodies in chinese patients with membranous nephropathy,” Medical Science Monitor, vol. 22, pp. 1630–1636, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Qin, L. H. Beck Jr., C. Zeng et al., “Anti-phospholipase A2 receptor antibody in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1137–1143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Qin, M. Zhang, W. Le et al., “Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 27, no. 10, pp. 3195–3203, 2016. View at Publisher · View at Google Scholar
  26. H.-R. Dong, Y.-Y. Wang, X.-H. Cheng et al., “Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy,” PLoS ONE, vol. 11, no. 5, Article ID e0156263, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Akiyama, M. Akiyama, E. Imai, T. Ozaki, S. Matsuo, and S. Maruyama, “Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy,” Clinical and Experimental Nephrology, vol. 19, no. 4, pp. 653–660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Hihara, M. Iyoda, S. Tachibana et al., “Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy,” PLoS ONE, vol. 11, no. 6, Article ID e0158154, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Iwakura, N. Ohashi, A. Kato, S. Baba, and H. Yasuda, “Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the Glomeruli of Japanese patients with idiopathic membranous nephropathy,” PLoS ONE, vol. 10, no. 9, Article ID e0138841, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Gunnarsson, W. Schlumberger, and J. Rönnelid, “Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis,” American Journal of Kidney Diseases, vol. 59, no. 4, pp. 585-586, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. C. P. Larsen, N. C. Messias, F. G. Silva, E. Messias, and P. D. Walker, “Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies,” Modern Pathology, vol. 26, no. 5, pp. 709–715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Xie, Y. Li, J. Xue et al., “Renal Phospholipase A2 Receptor in Hepatitis B Virus-Associated Membranous Nephropathy,” American Journal of Nephrology, vol. 41, no. 4-5, pp. 345–353, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. Y.-C. Ge, B. Jin, C.-H. Zeng et al., “PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy,” BMC Nephrology, vol. 17, no. 1, article no. 185, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. M. E. G. Timmermans, J. G. M. C. Damoiseaux, P. T. J. Heerings-Rewinkel et al., “Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: A cohort study,” American Journal of Clinical Pathology, vol. 142, no. 1, pp. 29–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. A. K. Stahl, “M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 1883–1890, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Kanigicherla, J. Gummadova, E. A. McKenzie et al., “Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy,” Kidney International, vol. 83, no. 5, pp. 940–948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Ruggenenti, H. Debiec, B. Ruggiero et al., “Anti-Phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 10, pp. 2545–2558, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Dahan, H. Debiec, E. Plaisier et al., “Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up,” Journal of the American Society of Nephrology, vol. 28, no. 1, pp. 348–358, 2017. View at Publisher · View at Google Scholar
  39. J. Wang, Q. Xie, Z. Sun et al., “Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study,” BMC Nephrology, vol. 18, no. 1, 2017. View at Publisher · View at Google Scholar
  40. L. H. Beck Jr., F. C. Fervenza, D. M. Beck et al., “Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1543–1550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. P. Bech, J. M. Hofstra, P. E. Brenchley, and J. F. Wetzels, “Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1386–1392, 2014. View at Publisher · View at Google Scholar
  42. E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. A. K. Stahl, “PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system,” PLoS ONE, vol. 9, no. 10, Article ID e110681, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Svobodova, E. Honsova, P. Ronco, V. Tesar, and H. Debiec, “Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1839–1844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Kanda, S. Horita, T. Yanagihara, A. Shimizu, and M. Hattori, “M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy,” Pediatric Nephrology, vol. 32, no. 4, pp. 713–717, 2017. View at Publisher · View at Google Scholar · View at Scopus
  45. L. N. Cossey, P. D. Walker, and C. P. Larsen, “Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy,” Pediatric Nephrology, vol. 28, no. 12, pp. 2307–2311, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Kumar, A. Varma, R. Nada et al., “Primary Membranous Nephropathy in adolescence A Prospective study,” Nephrology, 2016. View at Publisher · View at Google Scholar
  47. H. Dai, H. Zhang, and Y. He, “Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: An updated meta-analysis,” Scientific Reports, vol. 5, article no. 8803, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A.-E. Van De Logt, J. M. Hofstra, and J. F. M. Wetzels, “Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: Seroconversion after prolonged follow-up,” Kidney International, vol. 87, no. 6, pp. 1263-1264, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M.-J. Guerry, P. Vanhille, P. Ronco, and H. Debiec, “Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy,” Kidney International, vol. 89, no. 6, p. 1399, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Stehlé, V. Audard, P. Ronco, and H. Debiec, “Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 30, no. 6, pp. 1047–1050, 2015. View at Publisher · View at Google Scholar
  51. A. S. De Vriese, R. J. Glassock, K. A. Nath, S. Sethi, and F. C. Fervenza, “A Proposal for a serology-based approach to membranous nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 421–430, 2017. View at Publisher · View at Google Scholar
  52. M. Waldman, L. H. Beck, M. Braun, K. Wilkins, J. E. Balow, and H. A. Austin, “Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab,” Kidney International Reports, vol. 1, no. 2, pp. 73–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. L. F. Quintana, M. Blasco, M. Seras et al., “Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy,” Transplantation, vol. 99, no. 8, pp. 1709–1714, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Gupta, H. Fattah, R. Ayalon et al., “Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation,” Clinical Transplantation, vol. 30, no. 4, pp. 461–469, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Seitz-Polski, C. Payré, D. Ambrosetti et al., “Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: A case series of 15 patients,” Nephrology Dialysis Transplantation, vol. 29, no. 12, pp. 2334–2342, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Kattah, R. Ayalon, L. H. Beck Jr. et al., “Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy,” American Journal of Transplantation, vol. 15, no. 5, pp. 1349–1359, 2015. View at Publisher · View at Google Scholar
  57. A. Behnert, M. J. Fritzler, B. Teng et al., “An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor,” PLoS ONE, vol. 8, no. 4, Article ID e61669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Fresquet, T. A. Jowitt, and J. Gummadova, “Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 302–313, 2015. View at Publisher · View at Google Scholar
  59. L. Kao, V. Lam, M. Waldman, R. J. Glassock, and Q. Zhu, “Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 291–301, 2015. View at Publisher · View at Google Scholar
  60. L. H. Beck, “The dominant humoral epitope in phospholipase a2 receptor-1: Presentation matters when serving up a slice of π,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 237–239, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Seitz-Polski, G. Dolla, C. Payre et al., “Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 27, no. 5, pp. 1517–1533, 2016. View at Publisher · View at Google Scholar
  62. H. C. Stanescu, M. Arcos-Burgos, A. Medlar et al., “Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 364, no. 7, pp. 616–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Bullich, J. Ballarín, A. Oliver et al., “HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 2, pp. 335–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Sekula, Y. Li, H. C. Stanescu et al., “Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies,” Nephrology Dialysis Transplantation, vol. 32, no. 2, pp. 325–332, 2017. View at Publisher · View at Google Scholar
  65. M. Saeed, M. L. Beggs, P. D. Walker, and C. P. Larsen, “PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes,” Genes and Immunity, vol. 15, no. 8, pp. 556–561, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. C. P. Larsen, M. L. Beggs, P. D. Walker, M. Saeed, J. M. Ambruzs, and N. C. Messias, “Histopathologic effect of apol1 risk alleles in PLA2r-associated membranous glomerulopathy,” American Journal of Kidney Diseases, vol. 64, no. 1, pp. 161–163, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Lv, W. Hou, X. Zhou et al., “Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy,” Journal of the American Society of Nephrology, vol. 24, no. 8, pp. 1323–1329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Le, J. Shi, T. Zhang et al., “HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 5, pp. 1642–1650, 2017. View at Publisher · View at Google Scholar
  69. Z. Cui, L. Xie, F. Chen et al., “MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 5, pp. 1651–1664, 2017. View at Publisher · View at Google Scholar
  70. M. Thiri, K. Honda, K. Kashiwase et al., “High-density Association Mapping and Interaction Analysis of PLA2R1 and HLA Regions with Idiopathic Membranous Nephropathy in Japanese,” Scientific Reports, vol. 6, Article ID 38189, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. M. J. H. Coenen, J. M. Hofstra, H. Debiec et al., “Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 24, no. 4, pp. 677–683, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. C. D. Short, J. Feehally, R. Gokal, and N. P. Mallick, “Familial membranous nephropathy.,” BMJ, vol. 289, no. 6457, pp. 1500–1500, 1984. View at Publisher · View at Google Scholar
  73. L. Lin, W. M. Wang, X. X. Pan et al., “Biomarkers to detect membranous nephropathy in Chinese patients,” Oncotarget, vol. 7, no. 42, pp. 67868–67879, 2016. View at Publisher · View at Google Scholar
  74. C. P. Larsen, L. N. Cossey, and L. H. Beck, “THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity,” Modern Pathology, vol. 29, no. 4, pp. 421–426, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Hoxha, T. Wiech, P. R. Stahl et al., “A mechanism for cancer-associated membranous nephropathy,” New England Journal of Medicine, vol. 374, no. 20, pp. 1995-1996, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Hoxha, L. H. Beck, T. Wiech et al., “An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain–Containing 7A–Specific Antibodies in Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 520–531, 2017. View at Publisher · View at Google Scholar
  77. N. M. Tomas, E. Hoxha, A. T. Reinicke et al., “Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy,” Journal of Clinical Investigation, vol. 126, no. 7, pp. 2519–2532, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Ayalon and L. H. Beck, “Membranous nephropathy: not just a disease for adults,” Pediatric Nephrology, vol. 30, no. 1, pp. 31–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Menon and R. P. Valentini, “Membranous nephropathy in children: Clinical presentation and therapeutic approach,” Pediatric Nephrology, vol. 25, no. 8, pp. 1419–1428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Debiec, V. Guigonis, B. Mougenot et al., “Brief report: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies,” New England Journal of Medicine, vol. 346, no. 26, pp. 2053–2060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. J. L. Nortier, H. Debiec, Y. Tournay et al., “Neonatal disease in neutral endopeptidase alloimmunization: Lessons for immunological monitoring,” Pediatric Nephrology, vol. 21, no. 10, pp. 1399–1405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Vivarelli, F. Emma, T. Pellé et al., “Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies,” Kidney International, vol. 87, no. 3, pp. 602–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. D. H. Sandberg, C. W. Bernstein, R. M. McIntosh, R. Carr, and J. Strauss, “Severe steroid-responsive nephrosis associated with hypersensitivity,” The Lancet, vol. 309, no. 8008, pp. 388–391, 1977. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Abdel-Hafez, M. Shimada, P. Y. Lee, R. J. Johnson, and E. H. Garin, “Idiopathic Nephrotic Syndrome and Atopy: Is There a Common Link?” American Journal of Kidney Diseases, vol. 54, no. 5, pp. 945–953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Debiec, F. Lefeu, M. J. Kemper et al., “Early-childhood membranous nephropathy due to cationic bovine serum albumin,” New England Journal of Medicine, vol. 364, no. 22, pp. 2101–2110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Prunotto, M. L. Carnevali, G. Candiano et al., “Autoimmunity in membranous nephropathy targets aldose reductase and SOD2,” Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 507–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Bruschi, M. L. Carnevali, C. Murtas et al., “Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens,” Journal of Proteomics, vol. 74, no. 10, pp. 2008–2017, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. C. Murtas, M. Bruschi, G. Candiano et al., “Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1394–1400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Kimura, N. Miura, H. Debiec et al., “Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy,” Clinical and Experimental Nephrology, vol. 21, no. 1, pp. 117–126, 2017. View at Publisher · View at Google Scholar